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Contribution to the field 
 
We are aware that a number of different activities and treatments have been recommended for 
COVID-19, some of which have resulted in appreciable price increases as well as unintended 
consequences including suicides. This is a concern certainly among Asian countries with high co-
payment levels and issues of affordability. As a result, an urgent need to assess changes in the 
utilization and prices of pertinent medicines and equipment among community pharmacists in the 
early stage of the pandemic to provide future direction alongside the influence of ongoing preventative 
measures. We believe this is the first study conducted among Asian countries to address this, with the 
findings helping to provide future direction.  This includes considerable increases in utilization and 
prices of antimicrobials in some countries, which needs urgent addressing. Encouragingly though 
appreciable increases in vitamins/ immune boosters and PPE.  The  appreciable price rises in some 
settings needs addressing in view of the consequences of available resources in other areas. 
However, this was not universal with price controls in some of the Asian countries. Community 
pharmacists and others can provide public health educational input as well as help address 
unintended consequences from the pandemic.  
 
Abstract 
Background: Countries have introduced a variety of measures to prevent and treat COVID-19 with 
medicines and personal protective equipment (PPE), with some countries adopting preventative 
strategies earlier than others. However, there has been considerable controversy surrounding some 
treatments. This includes hydroxychloroquine where the initial hype and misinformation lead to 
shortages, price rises and suicides. Price rises and shortages have also been seen for PPE. Such 
activities can have catastrophic effects on patients where there are high co-payment levels and issues 
of affordability. Consequently, there is a need to investigate this further. Objective: Assess changes 
in the availability, utilisation and prices of relevant medicines and PPE during the pandemic among a 
range of Asian countries. Our approach: Narrative literature review combined with interviews among 
community pharmacists to assess changes in consumption, prices and shortages of medicines and 
PPEs from beginning of March until end of May 2020. In addition, suggestions on ways to reduce 
misinformation. Results: 308 pharmacists took part from 5 Asian countries. There was an appreciable 
increase in the utilisation of antimicrobials in Pakistan (in over 88% of pharmacies), with lower 
increases or no change in Bangladesh, India, Malaysia and Vietnam. Encouragingly, there was 
increased use of Vitamins/ immune boosters and PPE across the countries, as well as limited price 
rises for antimicrobials in India, Malaysia and Vietnam, although greater price rises seen for 
analgesics and Vitamin C/ immune boosters. Appreciable price increases were also seen for PPE 
across some countries. Conclusion: Encouraging to see increases in utilisation of vitamins/ immune 
boosters and PPE. However, increases in the utilisation and prices of antimicrobials is a concern that 
needs addressing alongside misinformation and any unintended consequences from the pandemic. 
Community pharmacists can play key role in providing evidence-based advice, helping to moderate 
prices, as well as helping address some of the unintended consequences of the pandemic.   
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1. Introduction 
 
1.1 General and Asia 
The coronavirus disease 2019 (COVID-19) pandemic was first identified in Wuhan, China, during 
December 2019, and by 27 September 2020 there were 32.731 million cases and over 990,000 
deaths worldwide giving a case fatality ratio (CFR) among confirmed cases of  3.03% (1-3). This 
included over 6.721million confirmed cases in the World Health Organization (WHO) South East 
Asian Region, including Bangladesh and India, with over 110,000 deaths, giving a CFR 1.65% and 
the Western Pacific Region with over 600,000 reported cases and over 13,000 deaths giving a CFR 
2.187% by 27 September 2020 (1). The lower prevalence and mortality rates among the WHO 
Western Pacific countries, including Malaysia, Korea, and Vietnam, compared with Bangladesh, India, 
and Pakistan (Table 1), appears to reflect early proactive testing and lockdown policies, combined 
with other factors, building on the lessons learnt from earlier pandemics (Table 2), even with 
appreciable under-reporting in Bangladesh, India, and Pakistan (2, 4-14).  A similar situation has been 
seen in Taiwan with the National Health Command Centre including the Central Epidemic Command 
Centre rapidly instigating educational activities, active tracking systems, accelerated production of 
personal protective equipment (PPE), lockdown, and quarantining measures (15, 16). By early April 
there were less than 400 confirmed cases in Taiwan among its 23 million citizens (15, 16), with only 
513 confirmed cases by 29 September and 7 deaths (17). We have also seen low prevalence and 
mortality rates among a number of African countries that instigated pro-active measures early 
compared with high income countries such as Western European countries and the USA (1, 18). 
Early engagement with citizens is crucial with preventing the spread of COVID-19 with countries such 
as Korea, Malaysia, Taiwan and Vietnam learning from earlier pandemics (15, 19). This compares 
with for instance Iran where the first cases of COVID-19 were confirmed on 19 February 2020 and by 
March 8 there were 6,566 confirmed cases and 194 deaths (20, 21). Some preventative measures 
were introduced Mid March to help reduce the spread of the virus, which included awareness 
campaigns, closing of educational facilities and disinfecting busy places (20-23) alongside a national 
screening programme but without widespread testing (21). However, stricter travel bans were only 
introduced at the end of March following travels during the Iranian New Year (21). This lack of early 
pro-activity may well have contributed to Iran having the highest prevalence rates (443086) and 
deaths (25394) due to COVID-19 in the WHO Eastern Mediterranean region by 27 September 2020 
including Pakistan (Table 1) despite concerns with economic sanctions (1, 24, 25).  
 
 
The active tracking systems in for instance in Taiwan and Vietnam compare with Pakistan where by 3 
April 2020 only 30,308 laboratory tests had been conducted of which 2,450 tested positive (26). We 
are aware though that over-crowding as well as a lack of clean water and sanitation in Bangladesh, 
India, and Pakistan will increase infection rates unless adequately addressed compared with higher 
income countries (12, 27-30). This is in addition to ongoing challenges with the subclinical 
manifestation of COVID-19 across all populations (31).  
 
Insert Table 1 
 
Adequate prevention and management of patients with COVID-19 is also hindered in Bangladesh, 
India and Pakistan compared with Malaysia, South Korea, and Vietnam, with high levels of patient co-
payments to purchase medicines and other treatments, which can be catastrophic for families if 
members become ill (12, 32, 33).  For instance in Bangladesh, an appreciable number of households 
are forced to sell their assets or borrow money to fund care when family members become ill affecting 
care delivery (12). This typically includes the cost of medicines as seen in patients with type 2 
diabetes (T2DM), where medicine costs account for 83.5% of total direct medical costs, which is 
typically out-of-pocket (12, 34). In India, up to 39 million people have been pushed into poverty each 
year due to healthcare co-payments; however, this is beginning to change with ongoing reforms to 
provide health insurance coverage for up to 100 million families in poverty (32, 35-37). However, this 
is changing with recent initiatives in India to control the prices of essential medicines as well as 
encourage the use of generic medicines where possible (38, 39). In addition, convergence of 
healthcare spending towards OECD average spending levels with movement towards universal 
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healthcare in the coming years although affordability of care for the poor will remain a continuing 
challenge (40-43).  
 
In Pakistan, there have been concerns with healthcare management at the provincial level following 
devolution, although this is not universal as seen with the recent COVID-19 pandemic (33, 44, 45). 
This is a concern with over 40% of the population currently living below the poverty line, and high 
rates of co-payments at over 78% of total healthcare expenditure with potentially catastrophic 
consequences if family members become ill (33, 46-48). The situation has been made worse in 
Pakistan in recent years with a rise in both infectious and non-infectious diseases. In 2019, there was 
a rise in the prevalence of dengue, HIV/ AIDS, malaria, measles and typhoid, compared to previous 
years, enhanced by consumption of contaminated water and food as well as environmental pollution 
even before the COVID-19 pandemic (49). Consequently, there are concerns that COVID-19 could 
further overwhelm the healthcare system. Having said this, knowledge, attitude and practices towards 
COVID-19 appeared satisfactory among healthcare professionals in Pakistan with a high percentage 
having a positive attitude towards prevention and management; however, there were some 
misconceptions that need to be addressed going forward (50, 51). There were concerns though about 
the extent of preventative practices among university students and employees despite good 
knowledge and attitudes towards COVID-19 (52).  
 
There has also been a lack of intensive care unit (ICU) beds and ventilators among public hospitals in 
Bangladesh to treat patients with severe COVID-19, with a similar situation in India and Pakistan (12, 
26, 27, 49, 53, 54), affecting care delivery. We have seen countries in Africa respond to the challenge 
of lack of ventilators through instigating local design with the help of universities, with increased local 
production of hand sanitisers and other preventative measures including face shields and splash 
masks to reduce the spread of the virus as well as improve management once patients are in hospital 
(18, 55) providing direction to others.  Local production of essential preventative equipment is likely to 
grow across countries to reduce future shortages (18, 19). Compounding the situation in Bangladesh, 
India, and Pakistan, certainly with respect to available resources to fund prevention and treatment of 
COVID-19, are also high prevalence rates of non-communicable diseases (NCDs) including coronary 
vascular disease (CVD), hypertension and diabetes (12, 33, 47, 56-58). This will necessitate changing 
models of care with increasing use of all healthcare professionals, exacerbated by the current 
situation with COVID-19 (59-62).This is in addition to continuing concerns with funding treatments for 
other infectious diseases, which, as mentioned, appear to be increasing in Pakistan (12, 35, 49, 63, 
64). Alongside this, there appears a general shortage of medicines to treat diseases in Pakistan not 
help by concerns with affordability among manufacturers (65, 66).  
 
The situation is different in Malaysia with a public healthcare system funded via general taxation in 
addition to a private healthcare system, which includes dispensing general practitioners (67, 68). The 
cost of medicines still accounts though for an appreciable proportion of total costs in the public 
healthcare system in Malaysia. There is though an active procurement process as well as demand-
side measures encouraging the prescribing of generics as part of ongoing measures to help contain 
costs (67) similar to ongoing measures in India (38).  The final agreed price for essential medicines in 
the public system should also ideally be no more than three times the International Reference Price 
(IRP) (67). However, there are currently a lack of price controls for medicines and other technologies 
in the private sector including mark-ups, which can add to the cost of medicines (69, 70). This lack of 
control is seen in the price of medicines for treating ischaemic heart disease (IHD) where the lowest 
price of generics or originator brands to treat IHD were 10.77 and 24.09 times respectively above 
IRPs, and can make these medicines  unaffordable for the average worker who purchases them in 
community pharmacies rather than attending primary healthcare clinics (PHCs) with their long waiting 
times (71-73). Currently in Malaysia, community pharmacists have a lesser of a role in dispensing 
medicines than seen in many other countries due to an appreciable number of dispensing physicians 
(74, 75). This needs to be addressed especially in patients with chronic diseases such as type 2 
diabetes (T2DM) to improve their care given appreciably increased rates in recent years (76-78). In 
the meantime, pharmacists do have an important role in the management of acute respiratory tract 
infections such as coughs and colds, for gastro-intestinal ailments (79), as well as minor ailments 
generally (80) in Malaysia, helped by the long waiting times to see healthcare professionals in PHCs 
(72).  
 
Social insurance coverage has increased in Vietnam in recent years to reduce the burden of out-of-
pocket payments (81, 82). However, out-of-pocket payments still exist, with health insurance only 
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covering part of the costs with potentially distressing consequences for a minority of families when 
members become ill (81, 83). As a result, community pharmacists continue to play a key role in 
managing diseases in Vietnam with for instance over 80% of people typically visiting a pharmacist first 
for their illness. These scenarios are common especially in rural areas to conserve costs for patients 
and enhance profits for pharmacists; however, rates of self-purchasing of medicines are lower than 
before enhanced by increased social insurance (74, 84-86).  Despite this, the costs of medicines can 
still be a concern in Vietnam with high costs versus IRP (87).  
 
Overall across Asia, pharmacies are often the main source of healthcare for patients across given 
lack of waiting times, extended opening hours, and high co-payment levels (64, 76, 88-92), mirroring 
the situation in other countries (93-95). Consequently, have a key role to play in current and future 
pandemics. 
 
1.3 Management Strategies to Prevent and Treat COVID-19 – General and across Asian 
countries 
COVID-19 is transmitted from person to person principally through respiratory droplets and aerosol 
transmission forming the basis of preventative measures across countries (Table 2) (12, 96-102). 
Preventative messages appear to be accepted by the population with for instance 85.8% of citizens in 
Pakistan in a recent survey stating they regularly wear face masks and 88.1% undertake 
handwashing to try and prevent the spread (103). However, as mentioned, there were concerns 
though about the extent of preventative practices among university students and employees (52).  
 
Current evidence suggests increased morbidity and mortality from COVID-19 is associated with 
underlying health conditions including hypertension, CVD, diabetes, smoking, shortness of breath, 
chronic obstructive pulmonary disease (COPD) and blood types (104-111). Ethnicity may also be 
important with patients in the United Kingdom of South Asian origin at appreciably increased risk of 
dying from COVID-19 versus those of white ethnicity (112-116), which is a concern in Asia along with 
high rates of smoking and growing rates of chronic NCDs including CVD and diabetes (12, 56, 58, 
117-119). However, currently there appears to be no cure for patients with COVID-19; however, a 
number of medicines have been proposed, rejected or are still undergoing trials (12, 120-123). This 
means that preventative measures are very important to reduce morbidity and mortality from COVID-
19. In addition, predictive models in hospitals to better target resources and treatments (124, 125). 
 
The most promising treatment to date appears to be dexamethasone, shown in the UK Recovery 
Trials to reduce the number of deaths in ventilated patients and in those receiving oxygen only (126). 
Remdesivir has also shown encouraging results despite earlier concerns in an underpowered study 
(127-129), although there appears less benefit in patients with moderate COVID-19, with studies still 
ongoing to fully assess its future role in treatment (130, 131). Triple antiviral therapy has also shown 
promise although patient numbers in the trial are small (132). Most controversy surrounds the use of 
chloroquine or hydroxychloroquine with or without azithromycin for prevention or treatment following 
initial studies in China (133-135). There were concerns about the lack of comparisons in the initial 
studies alongside potential harm including cardiac side-effects (134, 136, 137). A number of recent 
studies have endorsed these concerns including the UK Recovery Trial (133, 138-140), resulting in 
the WHO and the National Institute of Health (NIH) in the US halting the use of hydroxychloroquine in 
their studies (123, 129, 139, 141, 142). However, hydroxychloroquine is still recommended for 
prophylaxis in India with Chatterjee et al. (2020) demonstrating that hydroxychloroquine was 
associated with a significant reduction in the chances of healthcare workers getting COVID-19 (143-
145). The Government and others in Malaysia also initially endorsed hydroxychloroquine helped by 
additional supplies from India (146), with continued endorsement at lower doses in early June (6, 147, 
148), with the Government in Pakistan banning exports for fear of shortages (149), although later 
reversed (150). There have also been ongoing studies with chloroquine in Vietnam (151). However, 
hydroxychloroquine is no longer recommended in Malaysia following recent analysis of data collected 
from 500 cases, which showed no effect (152).  
 
There have been similar controversies surrounding lopinavir/ritonavir, which is endorsed in India but 
now dropped from the WHO Solidarity study and the UK Recovery study due to concerns with its 
effectiveness (123, 145, 153). Consequently, there is a need to ensure that recommended strategies 
are evidence based given current controversies and redactions (123, 136, 154, 155). This is because 
misinformation can have devastating consequences, which include increasing the cost of medicines 
as well as increasing hospitalisations and deaths from poisoning from hydroxychloroquine (12, 156-
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159). In addition, diverting scarce monies away from purchasing necessary personal protective 
equipment (PPE) and monies to treat priority infectious and non-infectious diseases. Table 2 
documents current prevention and other strategies among selected Asian countries to help provide 
future direction, building on published activities for Bangladesh (12).  
 
Insert Table 2 
 
Insert Figure 1 
 
Unintended consequences of COVID-19 include concerns that patients with NCDs are not attending 
follow-up clinics and not receiving their medicines (12, 60), which is an increasing concern among 
Asian countries including India (59, 160). In addition, concerns that the mental health of the 
population in terms of their emotional, psychological, and social impact, is being adversely affected by 
the pandemic. This is likely to be the case among Asian countries with cultures highly dependent on 
socialisation in terms of support and connectedness, with such activities appreciably affected by 
lockdown and other measures (161). However, we are aware that issues of mental health are being 
addressed through increased telemedicine approaches in lower- and middle-income countries 
(LMICs) (162), and this is likely to continue. Restrictions on movement with lockdown measures, as 
well as concerns surrounding COVID-19 transmission, have also reduced immunisation rates in India 
and Pakistan in recent months, which also needs addressing (163, 164). Community pharmacists can 
help here including enhancing adherence to medicines in patients with chronic NCDs as well as give 
guidance and public health education on prevention and possible treatments for patients with 
suspected COVID-19 (12, 89, 165-168).  
 
Pharmacists and others can also help balance demand and supply of medicines, which is essential in 
countries where there are high patient co-payment levels and concerns with medicine availability (12, 
75). This is particularly important if shortages lead to high prices for pertinent medicines and PPE with 
potentially catastrophic consequences for families.  
 
1.4 Study Objectives 
Consequently, we believe there is a need to study the availability and prices of suggested medicines 
and PPE to prevent and treat COVID-19 among pharmacies and drug stores in Asian countries with 
high rates of both infectious and communicable diseases, as well as issues regarding co-payments to 
provide future direction. We have published on these issues in Bangladesh, and we have seen price 
rises in other LMICs (169-171). We now wish to compare and contrast the findings in Bangladesh with 
India and Pakistan with similar high co-payment levels and high rates of both infectious and non-
infectious diseases, although with price controls in India (38), along with Malaysia and Vietnam where 
community pharmacists are active especially for minor ailments. In addition, where 
hydroxychloroquine has also been endorsed for the management of patients with COVID-19 certainly 
initially.  
 
In addition, contrast countries where pro-active strategies initially (Table 2) appear to have 
appreciably lowered prevalence and mortality rates from COVID-19 (Korea, Malaysia and Vietnam) 
versus Bangladesh, India, and Pakistan despite low levels of testing in these countries certainly 
initially (Table 1). The combined findings can help provide future direction to all key stakeholder 
groups. 
 
2. Materials and Methods 
 
We adopted a similar multiple strategy approach to the paper of Haque et al. discussing activities in 
Bangladesh (12). This included updated information from a pragmatic review of the literature 
combined with a questionnaire survey among community pharmacies and drug store owners in India, 
Malaysia, Pakistan, and Vietnam, building on the findings in Bangladesh, to assess the current 
situation regarding usage patterns, prices, and availability of carefully selected medicines that could 
potentially be used in the management of COVID-19, as well as PPE in most countries, soon after the 
start of the pandemic (12). We also included herbal medicines in Pakistan and Vietnam as we are 
aware of their use in patients with COVID-19 among a number of LMICs despite concerns (172, 173). 
Medicines included pertinent antimalarials such as hydroxychloroquine, antibiotics such as 
azithromycin, analgesics (general including paracetamol), vitamins and immune boosters such as 
Vitamin C as well as PPE including face masks (Box 1). We just asked for impressions in the first 
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instance for changes in utilisation, prices, and shortages, from early March to end of May 2020 if this 
was the only information available due to issues of confidentiality (12). The baseline was early 2020, 
i.e. just before active preventative measures in a number of the countries (Table 1). More specific 
data on actual changes in utilisation and prices was asked if this was available; however, this did not 
include asking the pharmacists to break down changes in utilisation patterns and prices per month as 
this was deemed too problematic for this initial study.  
 
Box 1 – Open ended questions to community pharmacists in India regarding pertinent medicines and 
equipment to prevent and treat COVID-19 
 
• Country? 
• What changes in purchasing/ utilisation patterns have you noticed in your pharmacy from the 
beginning of March until the end of May for antimalarials (hydroxychloroquine), antibiotics (e.g. 
azithromycin and co-amoxiclav), multivitamins including Vitamin C and analgesics? The 
baseline is early 2020. Please base this information on invoices where possible or other 
information sources; otherwise, impressions 
• What changes in the prices have you noticed for pertinent medicines from the beginning of 
March until end May for antimalarials, antibiotics, multivitamins and analgesics (based on 
invoices or other information sources where possible). The baseline is early 2020. Please base 
this information on invoices where possible or other information sources; otherwise, 
impressions 
• Have there been any shortages for antimalarials, antibiotics, multivitamins and analgesics from 
the beginning of March until end May? If so, what has been the extent if known? 
• Similarly, for PPE including face masks, hand sanitisers and thermometers (utilisation, prices 
and shortages) from the beginning of March until the end May (baseline early 2020) - based 
again on invoices or other information sources/ impressions 
• Similarly for herbal medicines in Pakistan and Vietnam 
• What suggestions can you give the authorities to address misinformation regarding the current 
pandemic (if pertinent) as well as any inappropriate self-medication with antimicrobials for 
future pandemics given current concerns? 
 
 
Convenience sampling was used to select pharmacists through emails, telephone contact, personal 
contacts and other mechanisms. Similar to the initial study in Bangladesh (12), there was no sample 
size calculation as there was no previous data to base calculations upon at the start of the study. In 
addition, the studies undertaken in Malaysia, Pakistan, and Vietnam were pilot studies to help 
determine the need for additional studies. All questions were again open ended with data captured on 
Excel spreadsheets (Box 1). A more detailed description of the questionnaire can be found in Haque 
et al. (2020) (12). The replies from the community pharmacists were collated where possible into 
logical bands for comparisons between countries including the initial analysis from Bangladesh (12). 
These bands were not pre-defined as this was an exploratory study, with changes in prices based on 
local prices and not converted into a single currency such as US dollars using current exchange rates 
since ascertaining actual prices was not an objective of this study. The changes in utilisation and 
prices were absolute changes during the time period of the study.. Suggested strategies going 
forward for all key stakeholder groups also builds on the combined experiences of the co-authors. We 
have successfully used this approach before to provide future direction in LMICs (12, 86, 174-178).  
 
We believed that there would be price rises and shortages in other countries apart from Bangladesh. 
However, the nature and extent would depend on ongoing programmes within the country (Table 2) 
including greater price controls in India and Pakistan (38, 66).  
 
Ethical approval for this study was not required according to national legislation and institutional 
guidelines.  However, as before, all pharmacists freely provided the requested information having 
been given the opportunity to refuse to participate if wished. This is in line with previous studies 
undertaken by the co-authors in this and related areas including analysis of policies to enhance the 
rationale use of medicines and biosimilars, pricing policies and issues surrounding generics, which 
involved direct contact with health authority personnel and other key stakeholders (12, 86, 175, 179-
182). 
 
3. Results 
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Table 3 provides details of the number of pharmacists and drug store owners taking part including the 
pilot studies in Malaysia and Vietnam. There was a low refusal rate in Bangladesh (36.1%), India 
(18%) and Malaysia (0%), with pilot studies conducted among selected pharmacies in Pakistan and 
Vietnam. 
 
Insert Table 3 
 
We will first report on changes in utilisation patterns across the studied countries before reporting on 
any price changes and shortages. 
 
3.1 Utilisation 
Table 4 depict changes in the utilisation patterns for the various medicines, vitamins and PPE from 
the beginning of March until the end of May 2020 among the studied countries. Encouragingly, there 
was no change or decreased utilisation of antimalarials in an appreciable number of pharmacies in 
Bangladesh (51.2%), Malaysia (83.3%) and Vietnam, with no change in 45% of pharmacies in India, 
contrasting with Pakistan (no change in only 11.1%). There were differences in the utilisation patterns 
with antibiotics with increases seen in Bangladesh (70.6% of stores) and Pakistan (100% of 
pharmacies) compared with only 42.3% in India and little or no increase in either Malaysia or Vietnam 
(Table 4). 
 
Insert Table 4 
 
There were though appreciable increases in the utilisation of analgesics and Vitamin C/ immune 
boosters in both Bangladesh and India, and to a lesser extent in Malaysia and Vietnam, with 
increased use of Vitamin C/ immune boosters Pakistan during the study period. Encouragingly, there 
were increases in the utilisation of PPE across all countries where documented, some of which was 
substantial in line with recommendations.  Encouragingly as well, no increased use of herbal 
medicines in Pakistan contrasting with Vietnam. It is likely that we will continue to see increases in the 
utilisation of Vitamins/ immune boosters and PPE across countries if COVID-19 infection rates 
increase following easing of any lockdown measures.   
 
3.2 Price changes 
Table 5 depicts price changes for pertinent medicines and PPE during the study period. 
Encouragingly, there were limited price increases in Malaysia and Vietnam for antimalarials and 
antibiotics, with greater price rises seen for analgesics and Vitamin C/ immune boosters. There were 
also very limited increases in prices in India and Pakistan enhanced by price control measures (38, 
39, 66). As expected, price rises were seen in over 90% of pharmacies for PPE across studied 
countries, with substantial price rises seen particularly in Bangladesh.  
 
Insert Table 5 
 
3.3 Medicine and prevention shortages 
Perhaps not surprisingly, shortages of a number of medicines were seen (Table 6). This was 
especially the case for antimalarials in Bangladesh, India, Malaysia, and Pakistan, with shortages of 
antibiotics principally seen in Malaysia and Pakistan. Shortages of PPE were also seen among the 
countries studied reflecting ongoing preventative strategies among the countries (Table 2).  
 
Insert Table 6 
 
3.4 Potential ways forward to address misinformation and enhance appropriate use of 
medicines and equipment across sectors 
 
Possible strategies to address concerns regarding the management of COVID-19 and any unintended 
consequences especially in Bangladesh and India are included in Table 7. This builds on previous 
suggestions for Bangladesh only (12).  
 
Insert Table 7 
 
4. Discussion 
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We believe this is one of the first studies to assess the impact of COVID-19 on the utilisation, 
availability and price changes of pertinent medicines and PPE to prevent and treat patients with 
COVID-19 among Asian countries in the early stages of the pandemic. This is important as payments 
for medicines among a number of these LMICs can potentially be catastrophic for patients, and 
spending valuable resources on unproven medicines diverts scarce monies away from funding 
medicines in priority disease areas. Considerable increases in the prices of vitamins/ immune 
boosters and PPE is also a concern where this exists (Table 5), again diverting monies away from 
funding treatments in other priority disease areas, probably reflecting some of the shortages seen 
(Table 6). Greater monitoring of prices as well as increases in local production of medicines and PPE 
may be ways forward to reduce future price rises and shortages (19), and we will continue to monitor 
this building on ongoing initiatives among African and Asian countries (Table 1) (18) .   
 
It was encouraging to see appreciable increases in the utilisation of PPE as well as Vitamin C/ 
immune boosters across the studied countries (Table 4) suggesting that public health messages are 
getting through, building on positive experiences in Pakistan (50, 103). Alongside this, encouraging to 
see no change or decreased utilisation of antimalarials and antibiotics in over 50% of pharmacies 
India, Malaysia and Pakistan, similarly for antimalarials in Bangladesh. This is in line with initiatives by 
governments certainly in India, Malaysia, and Vietnam to try and restrict the sales of antimicrobials to 
reduce resistance development, which we see continuing. There are a number of initiatives that can 
be undertaken in Bangladesh and Pakistan to enhance the appropriate use of antimicrobials. This 
includes providing increased education and guidelines to pharmacists where there are concerns (90, 
183), as well as greater patient education. In addition, greater enforcement of any legislation banning 
the dispensing of antimicrobials without a prescription. Such activities have worked well in other 
countries including other LMICs (86, 93, 184-186) without the need for fines, which can be 
problematic and difficult to enforce (187). This is important in patients with COVID-19 since, as 
mentioned (Table 7), it can be difficult in practice to differentiate respiratory tract infections from 
COVID-19 in patients presenting with coughs and fever (188). Consequently, early referral for testing 
and subsequent management is encouraged where possible. 
 
The increased use of analgesics across a number of the countries studied is also in line with 
expectations (Table 4), and as mentioned, we would expect increased utilisation of vitamins/ immune 
boosters and PPE to continue if COVID-19 infection rates increase following any easing of lockdown 
measures.   
 
Table 7 highlights potential activities that can be undertaken by key stakeholder groups going forward 
including addressing unintended consequences. A key area is the level of misinformation seen 
especially surrounding chloroquine and hydroxychloroquine with potentially devastating 
consequences (156, 159, 189, 190). Consequently, as mentioned, there is a need to ensure that 
recommended strategies from Minsteries of Health and leading physician and pharmacy 
organisations are evidence based given the extent of redactions and concerns that have been seen to 
date (123, 136, 154, 155). Another key area from a public health viewpoint is addressing the 
unintended consequences of lockdown measures. This includes an increase in other infectious 
diseases if immunisation programmes and other measures are not undertaken as well as an increase 
in mental health disorders and other NCDs as a result of the pandemic (60, 61, 161, 163, 164). We 
are aware that lockdown measures in sub-Saharan Africa could result in up to 18 million additional 
cases of malaria and up to 30,000 additional deaths (191-193), with similar concerns in infected Asian 
countries. There are also considerable concerns with appreciably increased mortality in other 
infectious diseases if children are not being vaccinated (194). Consequently, avoided if possible. 
Telemedicine and other approaches can help with mental health concerns as well as concerns with 
other NCDs in LMICs (162), and this is likely to continue. However, mindful that any approach needs 
to take into account individual patient’s needs and their specific situation (195).  
 
Community pharmacists are likely to have an increasing role in the future across countries including 
LMICs as their knowledge and experience grows. This includes potentially instigating educational and 
other programmes to enhance adherence to medicines in patients with chronic NCDs given ongoing 
concerns as well as give guidance and public health education on prevention and possible treatments 
for patients with suspected COVID-19 (12, 89, 165-168). Their potential role also includes helping 
with immunization programmes with studies showing that when pharmacists provide immunizations, 
they substantially increase rates (196). Community pharmacists can also push for extended 
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prescription lengths where this is a concern and patients have difficulties with obtaining supplies. We 
will be exploring the unintended consequences in future research projects as these considerations are 
important in future planning. 
 
Limitations 
We are aware of a number of limitations with this study. These include the fact that we were only able 
to undertake pilot studies in a number of countries including Pakistan and Vietnam. In addition, we 
were unable to obtain exact details on changes in the utilisation and prices of pertinent medicines and 
PPEs from all the pharmacists visited due to issues of confidentiality and having the data readily to 
hand. We were also unable to undertake any time series analysis as we were primarily interested in 
changes post the pandemic, and this was not broken down by month. As a result, we did not adjust 
for any seasonality. However, we are confident our findings and ways forward for all key stakeholder 
groups can be helpful for future planning purposes including extending the role of community 
pharmacists across countries.  
 
5. Conclusion 
We have seen increases in utilisation and prices for antimalarials and antibiotics across countries 
arising from the COVID-19 pandemic, with considerable increases in some countries. This needs 
addressing through educational and other activities to prevent rises in resistance rates. Community 
pharmacies and others, including patient organisations, can also play a key role with improving 
prevention measures as well as reducing the impact of any misinformation given the consequences 
experienced among countries.  
 
Key stakeholder groups including community pharmacists and patient organisations can also help 
address the unintended consequences from lockdown and other activities including potential 
increases in infectious diseases and greater morbidity from NCDs, and we will be monitoring this in 
the future. Encouragingly, there was increased use of vitamins/ immune boosters and PPE among the 
Asian countries. However, the considerable price rises seen are a concern in countries with existing 
high co-payment levels and no government control on prices, which need addressing. Community 
pharmacists can again play a role here alongside the Government.    
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Tables and Figures 
 
Table 1 – Confirmed prevalence and mortality rates for COVID-19 in selected South East Asian and 
Western Pacific countries (27 September 2020)  
 
Country Population 
Size 
First recorded case Prevalence 
Rates 
Current 
deaths 
CFR rate 
Bangladesh 164,689,383 Early March 2020 
(12) 
357873 
 
 
5129 
 
 
1.43% 
India 1,380,004,385 30 January (27, 197) 5992532 
 
94503 
 
 
1.58% 
Malaysia 32,365,999 25 January (5, 6) 10769 
 
 
133 1.24% 
Pakistan 220,892,340 25/ 26 February 
2020 (26, 103, 198) 
310275 6457 2.08% 
South Korea 51,269,185 19 January 2020 (8, 
199) 
23611 
 
 
401 1.70% 
Vietnam  97,338,579 First case 23 
January; second 
1069 
 
35 3.27% 
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wave 6 March (7, 11, 
200) 
NB: Population figures taken from Worldometer data for 2020 (201-203) and epidemiology data from 
WHO (1). CFR = case fatality rate 
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Table 2 – Early activities instigated among selected Asian countries to help with prevention and 
treatment of COVID-19. 
 
Country Ongoing activities including dates where known 
Bangladesh 
(summary) (12) 
• First week of March 2020 – The Government started to postpone/ cancel 
all mass gatherings  
• 15 March 2020 – The Government banned all flights coming from Europe 
except the United Kingdom and on 16 March imposed a 14-day obligatory 
quarantine on all travellers entering Bangladesh 
• 16/19 March 2020 - The Government closed all educational institutes and 
instructed local administrations to ban political and religious rallies as well 
as social and cultural gatherings 
• 23 March 2020 - The Government announced the closure of all public and 
private offices and on 25 March declared the enforcement of lockdown 
measures for 10 days effective from March 26, which was further 
extended 
• 12 June 2020 – The Government introduced the concept of risk zones for 
the prevention of COVID-19  
• In addition, ongoing concerns with sufficient PPE; although gifts have 
helped 
India • 30 January 2020 – Surveillance strengthened at points of entry and in the 
community (197) 
• 6 February 2020 – The Government issued travel restrictions to China 
and anyone with a travel history from China from 15th January 2020 will 
be quarantined (204). The Ministry of Health instigated a 24 h/7 days-a-
week disease alert helpline to provide information including clinical 
guidance (145, 205), with the textile industry producing PPE to address 
shortages (206) 
• 8 March 2020 – 52 laboratories were identified by ICMR for undertaking 
testing for COVID-19 (207), now increases and all international 
passengers mandated to undergo universal medical screening (207) 
• 15 March 2020 - all movement suspended for foreigners through all 
Immigration Land Check Posts with only a few exceptions (Nepalese and 
Bhutanese nationals) 
• 22 March 2020: ‘Janata Curfew’ introduced with 14 hour lockdowns (145), 
all children under 10 and all elderly over 65 told to remain at home unless 
essential (208); Ministry of Pharma and Consumer Affairs instructed to 
take necessary action to regulate prices for PPE and other health related 
materials and to facilitate their availability in hospitals and the population 
(208) 
• 25 March 2020 - Further lockdown measures initiated for 21 days starting 
on 25 March  (27, 145, 209), and extended to 3 May (145) 
• 14 April 2020 – Lockdown extended until 3 May 2020 (210), and further 
lockdown extended for 2 weeks from 4 May 2020; however, variable 
activities across districts depending on current infection rates (211) 
Malaysia • 6 February 2020  – Updated travel restrictions from travellers coming from 
infected Provinces in China (212) 
• February 2020 – Ministry of Health in Malaysia appreciably upgraded 
health facilities and diagnostic capacity including a 86% increment in 
diagnostics laboratory capacity, a 89% increment in ICU capacity and a 
49% increase in the number of ventilators (from 526 to 1034 units); in 
addition hospitalising all COVID-19 positive patients (6) 
• 5 March 2020 – Expanded travel restriction list especially those coming 
from infected areas (5) 
• 16/ 18 March 2020 – Borders closed and Malaysian citizens not allowed 
to leave the country; all schools, universities and non-essential 
businesses also closed; and control of movement (5, 213, 214) 
13 
 
• 25 March 2020 – Current movement restrictions extended until 14 April, 
with the army deployed from 22 March onwards to help enforce 
movement restrictions (5, 215) 
• 15 April 2020 – The Government announces it will jail movement violators 
(214) 
• 29 April 2020 – Lockdown measures eased, e.g. easing of social 
distancing rules (216) 
• 30 April 2020 – testing capacity increased up to14,000 tests per day and 
soon up to 20,000 tests/ day, building on the experience with other 
infectious diseases including dengue and tuberculosis (6) 
• 10 May –  4 week extension to existing restrictions on movement and 
business until 9 June (217) 
• Early June (9 June onwards) – Most restrictions lifted on businesses (218) 
 
Overall, increasing compliance with movement restriction orders is seen as a 
major reason why a decrease in new COVID-19 cases was seen in Malaysia 
from mid-April onwards (5) 
Pakistan • 13 March 2020 – National co-ordination committee formed and all 
colleges and universities closed – further extended till end May 2020 (26, 
198, 219) 
• Mid-March 2020 – Quarantining of retuning travelers including those from 
religious festivals. However, system in some States over whelmed and 
becoming centers for infection with lack of facilities including hand 
sanitization (14, 220). In addition, start of sealing of borders (Iran and 
Afghanistan) (219) 
• Mid-March/ 17 March 2020 – Initially no national lockdown due to 
concerns with adults feeding themselves and their families if no longer 
working; however advice from the Ministry of Health on ways to reduce 
the spread of the virus including avoid public gatherings, regularly 
washing hands and social distancing including distancing from infected 
patients (220, 221) 
• Mid-March/ April – Government offering financial support to citizens and 
businesses to help address financial concerns during the pandemic (26, 
45) 
• 21 March 2020 – Pakistan banned International flights (222) 
• 24 March 2020 – National lockdown imposed urging citizens to stay 
indoors apart from food and medicines given rising prevalence rates and 
suspending railway operations until at least 31 March 2020. Lockdown 
aided by law enforcement officers and the military. Further extensions to 
14 April 2020  (54, 221-223) 
• 9 May 2020 – Lockdown lifted principally in view of economic needs; 
however, concerns that lifted too soon (224, 225). More recently, targeting 
of ‘hot spots’ to help control the spread (226, 227) 
South Korea • End January 2020 – Government establishing an emergency response 
committee (8) 
• 27 January 2020 – Korean Centre for Disease Control (CDC) directed 
private companies to help produce diagnostic reagents (8). By March 
100,000 kits were shipped daily and by 24 April 2020 118 institutions were 
available to run diagnostic tests (8, 228). Screening centres were 
established outside of hospitals and other institutions to help track and 
trace the virus enabling the country to perform 300,000 tests by late 
March (8, 229) 
• 12 February 2020 – Quarantining required for travellers from Hong Kong 
and Macau (8) 
• 21 February – Designating hospitals in Daegu for treating COVID-19 
patients, and building on this (229) 
• Mid-February to Early March – Initiatives to double the production of 
masks including companies re-purposing their garment factories, with the 
Government subsequently purchasing 80% of mask supplies from Korean 
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manufacturers, banning exports and setting price limits thereby helping to 
avert PPE shortages (8, 10, 229) 
• 7 March 2020 – GPS-App to go live to help enforce quarantining (8) 
• 23 March 2020 – Enhanced social distancing campaign (8) 
• 1 April 2020 – Required 14-day quarantine for all travellers with self-
reporting App 
• 8 April 2020 – Seoul closes bars, etc. (8) 
• 3 May 2020 – Relaxation of social distancing (10) 
• 11 May 2020 – School opening delayed apart from high school seniors (8) 
 
South Korea expanded its Epidemic Intelligence Service to help with early 
detection and to keep rates of infection low (8) 
Vietnam Figure 1 contains details of time lines and cases. 
 
In summary: 
• 10 January 2020 – Government reinforced temperature and health 
status screening at border gates for passengers arriving from Wuhan 
(230) 
• 20 January 2020 - 22 hospitals chosen for the treatment of suspected 
COVID-19 (230) 
• 31 January 2020 – All schools to remain closed (7, 230) 
• End January - Early February 2020, Government Taskforce Group under 
the Vice Prime-Minister on COVID-19 formed to direct and coordinate 
among the ministries (9, 200) with early measures including suspending 
flights from China and other epidemic areas, limiting crowds especially at 
festivals, suspending festivals not yet opened, asking people to wear 
masks in public places and limit travel (7, 200, 230). The media in 
Vietnam was heavily involved in conveying Government messages 
regarding prevention and other activities including SMS texts (200, 230) 
with concerns that some people are ignoring warnings 
• 7 February 2020 – Testing enhanced by the development of a test kit at 
Hanoi University of Science and Technology with further kits developed 
by Vietnam Academy of Science and Technology as well as other 
Universities from 3 March onwards (7) with 120 testing sites up and 
running by May 2020 
• February 2020 – First clinical guideline on diagnosis and treatment of 
COVID-19 patients introduced and updated in March as more data 
became available (200) 
• 28 February 2020 - Mandatory 14-day quarantine for all travellers 
entering Vietnam from a COVID-19 affected country (230) 
• 19 March 2020 - Mandatory use of the Hanoi Smart City app to monitor 
the health and movement of recovered confirmed cases, suspected 
cases, and people under quarantine (230) 
• 20 March 2020 – Strict quarantining for anyone entering the country 
(200) 
• 1 April 2020 – National lockdown measures introduced for 15 days and 
subsequently extended to 21 days in 28 out of 63 provinces (7, 200) 
• 13 April 2020 - Pharmacists are requested to ask patients buying 
medicines for acute respiratory infections such as coughs, fever, 
shortness of breath and colds to make a health declaration (231) 
• 23 April 2020 – Start of lifting of lockdown measures (232) 
 
In addition, pushing for self-sufficiency in the production of medicines and 
other technologies to help with future pandemics (233) 
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Table 3 – Details of pharmacists and drug stores owners across the countries 
 
Country Number of pharmacies/ Drug stores 
Bangladesh 170 
India 111 
Malaysia 12 
Pakistan 9 
Vietnam 6 
Total 308 
 
Table 4 – Changes in the utilisation for medicines and PPE between beginning March 2020 and end 
May 2020 among pharmacies across the countries (baseline = early 2020; n = number unless 
specified) 
 
  
 
NB: AM = antimalarial; AB = Antibiotic; AG = analgesics; Vit C = Vitamin C and other Vitamins and immune 
boosters; HM = herbal medicines, PPE = Face masks, thermometers and hand sanitisers. No change also 
includes situations where medicines were not dispensed without a prescription or not dispensed in community 
pharmacies (antimalarials and antibiotics) 
 
  
Change AM AB AG Vit C PPE AM AB AG Vit C PPE 
Decrease/ No demand (n) 9 5 2 25 23 21 1
No change (number) 78 45 4 16 6 25 41 15 10 2
Increase (not specified) to slight 
increase (number) 73 104 142 140 139 59 35 63 81 54
High increase to under 1.5 fold 
increase (number) 1 9 15 5 10
1.5 fold to 3 fold increase (n) 9 7 9 9 13 1 5 3 11 3
3 to 5 fold increase (number) 1 1 6 3
Above 5 fold increase (number) 6 3 8 49
Total number 170 170 170 170 170 111 111 111 111 111
% increase 48.8 70.6 97.6 90.6 95.3 55.0 42.3 67.6 90.1 98.2
% No change/ decrease 51.2 29.4 2.4 9.4 4.7 45.0 57.7 32.4 9.9 1.8
Bangladesh India
Change AM AB AG Vit C PPE AM AB AG Vit C HM AM AB AG Vit C HM PPE
Decrease/ No or low demand 
(number) 1 6 4 2 6
No change (number) 10 10 7 5 1 5 6 6
Increase (not specified) to slight 
increase/ high demand (n) 4 2 5 7 3 3 3 2 4
High increase to under 1.5 fold 
increase (n) 1 1 2 1 1 4 6
1.5 fold to 3 fold increase (n) 1 1 1 4 1 1 1
3 to 5 fold increase (number) 3 8
Above 5 fold increase (number) 2
Total (number) 12 12 12 12 12 9 9 9 9 9 6 6 6 6 6 6
% increase 16.7 16.7 41.7 58.3 100.0 88.9 100.0 44.4 88.9 33.3 0.0 0.0 33.3 66.7 0.0 100.0
% No change/ decrease 83.3 83.3 58.3 41.7 0.0 11.1 0.0 55.6 11.1 66.7 100.0 100.0 66.7 33.3 100.0 0.0
Malaysia Pakistan Vietnam
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Table 5 – Changes in the prices  of medicines and PPE between beginning March 2020 and end May 
2020 among pharmacies across the countries baseline = early 2020; n = number unless specified) 
 
 
 
NB: AM = antimalarial; AB = Antibiotic; AG = analgesics; Vit C = Vitamin C, other Vitamins and other immune 
boosters; HM = Herbal medicines; PPE = Face masks, thermometers and hand sanitisers 
 
Tables 6 – Shortages of medicines and PPE between beginning March 2020 and end May 2020 
among pharmacies across the countries baseline = early 2020; n = number unless specified) 
 
 
 
NB: AM = antimalarial; AB = Antibiotic; AG = analgesics; Vit C = Vitamin C, other Vitamins and other immune 
boosters; HM = Herbal medicines; PPE = Face masks, thermometers and hand sanitisers.  
 
  
Change AM AB AG Vit C PPE AM AB AG Vit C HM AM AB AG Vit C HM PPE
Data not available/ 
decrease (number) 6
No change (number) 10 12 7 7 8 7 8 7 8 5 4 5 6
Increase (no specified)/ 
slight increase (n) 4 4 1 2 1 2 1 1 2 1 6
High increase up to 2 fold 
increase (n) 2 3
2 - 4 fold increase (n) 1 2
Above 4 fold increase (n) 2 6
Total (number) 12 12 12 12 12 9 9 9 9 9 6 6 6 6 6 6
% increase 16.7 0.0 41.7 41.7 100.0 11.1 22.2 11.1 22.2 11.1 0.0 16.7 33.3 16.7 0.0 100.0
% No change/ decrease 83.3 100.0 58.3 58.3 0.0 88.9 77.8 88.9 77.8 88.9 100.0 83.3 66.7 83.3 100.0 0.0
Malaysia Pakistan Vietnam
Change AM AB AG Vit C PPE AM AB AG Vit C PPE 
Available/ no shortages (n) 78 140 129 105 34 33 100 109 84 13
Shortages (unspecified) (n) 63 18 36 57 114 25 9 2 43
Not available (number) 20 2 1 8
Shortages - some of the 
time (number) 9 10 4 8 14 53 2 2 25 55
Total 170 170 170 170 170 111 111 111 111 111
% Available/ no shortage 45.9 82.4 75.9 61.8 20.0 29.7 90.1 98.2 75.7 11.7
% Shortages 54.1 17.6 24.1 38.2 80.0 70.3 9.9 1.8 24.3 88.3
Bangladesh India
Change AM AB AG Vit C PPE AM AB AG Vit C HM AM AB AG Vit C HM PPE
Available/ no shortages/ 
not dispensed (number) 4 5 5 5 2 1 8 2 9 4 6 6 6
Shortages/ Stock outs (n) 8 7 7 7 10 5 6 1 4 2
Shortages (some of the 
time) - number 3 1 3 6
Decreased availability (n) 1 1
Total (number) 12 12 12 12 12 9 9 9 9 9 0 6 6 6 6 6
Available/ no shortage (% 
of total) 33.3 41.7 41.7 41.7 16.7 0.0 11.1 88.9 22.2 100.0 0.0 66.7 100.0 100.0 100.0 0.0
% Shortages (% of total) 66.7 58.3 58.3 58.3 83.3 100.0 88.9 11.1 77.8 0.0 100.0 33.3 0.0 0.0 0.0 100.0
Malaysia Pakistan Vietnam
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Table 7 – Key activities among stakeholder groups to improve prevention and management of 
patients with COVID-19  
 
Stakeholder Group Suggested Activities 
Government • Encourage early preventative measures to reduce the spread of any 
virus during future pandemics - building on the successes to date in 
Malaysia, South Korea, and Vietnam versus Bangladesh, India and 
Pakistan (Tables 1 and 2) 
• As part of this, utilize social media and other platforms to rapidly 
disseminate information regarding suggested activities to prevent the 
spread of viruses; however, mindful of the likely situation regarding 
the ability to social distance and the lack of clean water in a number 
of households in LMICs. This builds on the findings of Hayat et al. 
(2020) among citizens in Pakistan where following communication 
from the Government, in social media and other avenues 77.0% 
believed COVID-19 could be controlled successfully with practices of 
wearing masks (85.8%) and handwashing (88.1%) common among 
participants (103)  
• Encourage an evidence-based approach for decision making and 
recommendations given the controversies that still surround 
hydroxychloroquine (India) and Malaysia (until recently) as well as for 
lopinavir/ritonavir. In addition, the redaction of a number of recent 
papers relating to COVID-19 
• Alongside this, instigate measures to reduce the level of 
misinformation and its effects on diverting scarce resources away 
from funding medicines in other priority infectious and non-infectious 
diseases - in line with advice and recommendations from the Council 
for International Organisations of Medical Sciences (234). As part of 
this, explore the opportunity for financial consequences for 
companies spreading false misinformation and claims regarding 
potential treatments - building on activities in other countries (235, 
236) 
• Continue with ongoing and planned programmes to improve the 
management of patients with existing chronic NCDs as well as other 
infectious diseases to minimise unintended consequences arising 
from activities to reduce the spread of COVID-19. Alongside this, 
instigate activities to help reduce mental health issues, including 
stigma, arising from COVID-19 
• Similarly, for vaccination programmes – seek to address current 
concerns with reduced rates as a result of the pandemic and 
lockdown measures 
• Instigate/ enforce measures to reduce inappropriate self-purchasing 
of medicines including antimalarials and antibiotics where concerns – 
building on successful measures in other countries (86, 187) 
• Instigate measures to enhance the local production of medicines and 
PPE to address current shortages and keep prices rises to a 
minimum. Investigate the potential for formal price controls building 
on examples in Pakistan 
• When pertinent, adopt a phased approach to any easing of lockdown 
and other measures, with rapid re-introduction if needed (237) 
Physicians • Instigate a policy of evidence-based medicine in all aspects of care 
delivery starting in medical school and continuing post qualification 
building given the ongoing controversies surrounding the use of 
hydroxychloroquine and lopinavir- ritonavir in the prevention and 
management of COVID-19 
• As part of this, continue to ensure recommended treatments are 
evidence based through postgraduate training and other continuous 
professional development activities post qualification 
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• Continue to encourage where possible appropriate identification and 
management of patients with NCDs including CVD and diabetes, 
which includes encouraging adherence to prescribed medicines, 
giving rising rates of NCDs across Asia 
Pharmacists • Continue to encourage through education and other approaches/ 
recommended strategies to prevent the spread of COVID-19 
including preventative measures such as PPE. This includes 
providing education about COVID-19 and ways to reduce the spread 
of the virus which includes corporate responsibilities  
• Through stock control and other measures, try and ensure PPE and 
pertinent medicines, including suitable alternatives, that have proven 
to be beneficial for patients with COVID-19 are routinely available, 
and help ensure where possible that any price rises are kept to a 
minimum especially in countries with high co-payment levels 
• Encourage patients to seek testing and medical advice where 
COVID-19 is suspected, building on current strategies in Malaysia 
and Vietnam (Table 2), e.g. in Vietnam pharmacists are requested to 
ask patients buying medicines for acute respiratory infections such as 
coughs, fever, shortness of breath and colds to make a health 
declaration (231) 
• This is important since it can be difficult in practice to differentiate 
respiratory tract infections from COVID-19 in patients presenting with 
coughs and fever (188). As part of this, where pertinent, continue to 
argue/ council patients against the need for antibiotics where 
concerns 
• Work with patients to enhance adherence to medicines especially 
those for NCDs where it can be difficult for patients to attend clinics 
• Potentially become involved in vaccination programmes where there 
is unmet (196) 
Patients/ Patient 
organisations 
• Where possible, engage with social media and other key channels to 
promote evidence-based approaches to the prevention and 
management of COVID-19 given the current extent of misinformation 
to date, and ensure messages are as clear as possible and in a 
positive language (237) 
• In conjunction with this, seek to work with governments and other key 
stakeholder groups to minimise the impact of any misinformation 
(237) alongside working with them to seek to reduce the 
consequences of COVID-19 on mental health issues including stigma 
for healthcare professionals and patients 
• Continue educating patients through various channels, build on 
current self-management and other programmes, about the 
importance of self-management and adherence to prescribed 
treatments in patients with chronic NCDs – given the challenges of 
clinic attendance during lockdown measures 
• Explore new technologies including telemedicine and other 
approaches to reduce reliance on clinic attendance especially during 
pandemics as well as among rural patients in LMICs 
NB: NCDs = non-communicable diseases; PPE = personal protective equipment 
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Figure 1 – Time lines of prevalence rates and activities in Vietnam to reduce the spread of COVID-19 
and its consequences 
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